Related Experiment Video
Updated: Oct 7, 2025

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Skeletal muscle derived Musclin protects the heart during pathological overload
Malgorzata Szaroszyk1, Badder Kattih2,3,4, Abel Martin-Garrido5
1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Abstract:
Cachexia is associated with poor prognosis in chronic heart failure patients, but the underlying mechanisms of cachexia triggered disease progression remain poorly understood. Here, we investigate whether the dysregulation of myokine expression from wasting skeletal muscle exaggerates heart failure. RNA sequencing from wasting skeletal muscles of mice with heart failure reveals a reduced expression of Ostn, which encodes the secreted myokine Musclin, previously implicated in the enhancement of natriuretic peptide signaling. By generating skeletal muscle specific Ostn knock-out and overexpressing mice, we demonstrate that reduced skeletal muscle Musclin levels exaggerate, while its overexpression in muscle attenuates cardiac dysfunction and myocardial fibrosis during pressure overload. Mechanistically, Musclin enhances the abundance of C-type natriuretic peptide (CNP), thereby promoting cardiomyocyte contractility through protein kinase A and inhibiting fibroblast activation through protein kinase G signaling. Because we also find reduced OSTN expression in skeletal muscle of heart failure patients, augmentation of Musclin might serve as therapeutic strategy.
Insights
Reduced skeletal muscle Musclin (Ostn) worsens heart failure by impairing natriuretic peptide signaling. Restoring Musclin levels may offer a novel therapeutic strategy for heart failure patients with cachexia.
Area of Science:
- Cardiovascular Biology
- Skeletal Muscle Physiology
- Molecular Medicine
Background:
- Cachexia in chronic heart failure (CHF) patients is linked to poor prognosis, but its mechanisms driving disease progression are unclear.
- Myokine dysregulation from skeletal muscle wasting may exacerbate heart failure, yet specific pathways remain poorly understood.
Purpose of the Study:
- To investigate if altered myokine expression in skeletal muscle contributes to heart failure progression.
- To determine the role of the myokine Musclin, encoded by Ostn, in the context of heart failure and cachexia.
Main Methods:
- RNA sequencing of wasting skeletal muscles from mice with heart failure to identify differentially expressed genes.
- Generation of skeletal muscle-specific Ostn knockout and overexpression mouse models.
- Assessment of cardiac function, myocardial fibrosis, and molecular signaling pathways (protein kinase A and G).
Main Results:
- Reduced expression of Ostn, encoding Musclin, was observed in the skeletal muscle of mice with heart failure.
- Skeletal muscle-specific Ostn knockout exacerbated cardiac dysfunction and myocardial fibrosis.
- Overexpression of Musclin in skeletal muscle attenuated cardiac dysfunction and fibrosis.
- Musclin was found to enhance C-type natriuretic peptide (CNP) abundance, promoting cardiomyocyte contractility and inhibiting fibroblast activation.
Conclusions:
- Reduced skeletal muscle Musclin levels worsen heart failure progression and fibrosis.
- Musclin signaling, through CNP, protein kinase A, and protein kinase G, plays a protective role in the heart.
- Decreased OSTN expression in human heart failure skeletal muscle suggests Musclin augmentation as a potential therapeutic strategy.
Related Concept Videos
Structure of Cardiac Muscles
Compared to skeletal muscles, cardiac muscle cells are small and mostly have a single nucleus. Additionally, they are usually...
Specialized Characteristics of Cardiac Muscles
Cardiac muscle cells are smaller than skeletal muscles, averaging 10–20 mm in diameter and 50–100 mm in length. However, they have large energy demands for continuous contraction and relaxation. This energy is almost exclusively derived from aerobic metabolism of energy...
Satellite Stem Cells and Muscular Dystrophy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Pathophysiology of Cardiac Performance

